Order Article Reprints

Trédan O, Toulmonde M, Le Tourneau C, Montane L, Italiano A, Ray-Coquard I, De La Fouchardière C, Bertucci F, Gonçalves A, Gomez-Roca C, et al. Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort. Cancers. 2023; 15(13):3441. https://doi.org/10.3390/cancers15133441

Trédan, Olivier, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle Ray-Coquard, Christelle De La Fouchardière, François Bertucci, Anthony Gonçalves, Carlos Gomez-Roca, and et al. 2023. "Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort" Cancers 15, no. 13: 3441. https://doi.org/10.3390/cancers15133441

Trédan, O., Toulmonde, M., Le Tourneau, C., Montane, L., Italiano, A., Ray-Coquard, I., De La Fouchardière, C., Bertucci, F., Gonçalves, A., Gomez-Roca, C., You, B., Attignon, V., Boyault, S., Cassier, P. A., Dufresne, A., Tabone-Eglinger, S., Viari, A., Sohier, E., Kamal, M., ... Pérol, D. (2023). Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort. Cancers, 15(13), 3441. https://doi.org/10.3390/cancers15133441